Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,311 | -99,317 | -90,542 | -61,477 | -31,981 |
| Depreciation Amortization | -940 | 2,391 | 1,788 | 1,179 | 585 |
| Accounts receivable | 34,896 | -35,196 | -986 | -290 | -232 |
| Accounts payable and accrued liabilities | -618 | 68 | 2,441 | -844 | -1,060 |
| Other Working Capital | 10,290 | -30,654 | -33,728 | -24,782 | -14,113 |
| Other Operating Activity | -30,968 | 51,920 | 11,632 | 10,664 | 5,488 |
| Operating Cash Flow | $9,349 | $-110,788 | $-109,395 | $-75,550 | $-41,313 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -146,594 | 100,000 | N/A | N/A | N/A |
| PPE Investments | -48 | -1,740 | -1,558 | -1,148 | -736 |
| Investing Cash Flow | $-146,642 | $98,260 | $-1,558 | $-1,148 | $-736 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 648 | 458 | 458 | 7 |
| Financing Cash Flow | $N/A | $648 | $458 | $458 | $7 |
| Beginning Cash Position | 194,567 | 206,447 | 206,447 | 206,447 | 206,447 |
| End Cash Position | 57,274 | 194,567 | 95,952 | 130,207 | 164,405 |
| Net Cash Flow | $-137,293 | $-11,880 | $-110,495 | $-76,240 | $-42,042 |
| Free Cash Flow | |||||
| Operating Cash Flow | 9,349 | -110,788 | -109,395 | -75,550 | -41,313 |
| Capital Expenditure | -48 | -1,740 | -1,558 | -1,148 | -736 |
| Free Cash Flow | 9,301 | -112,528 | -110,953 | -76,698 | -42,049 |